Pulmatrix Announces Merger Agreement with Eos SENOLYTIX
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 15 2026
0mins
Source: PRnewswire
- Merger Agreement: Pulmatrix entered into a merger agreement with Eos SENOLYTIX on March 26, 2026, with an anticipated closing in Q3 2026, which will allow Eos's operations to continue as the core of the combined entity, enhancing market competitiveness.
- Financing Update: Concurrent with the merger agreement, Pulmatrix secured $1 million in preferred stock private placement from an affiliate of Eos, providing essential funding to support the merger process and operational needs.
- Financial Overview: As of March 31, 2026, Pulmatrix reported cash and cash equivalents of $3.324 million, down from $4.088 million as of December 31, 2025, indicating financial pressure but sufficient to fund operations until the merger is completed.
- R&D Expenditure: The company reported R&D expenses of less than $100,000 in Q1 2026, reflecting a halt in clinical development as management focuses on licensing or monetizing clinical assets to optimize resource allocation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PULM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PULM
About PULM
Pulmatrix, Inc. is a biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). Pulmatrix’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to enhance therapeutic delivery to the lungs by optimizing pharmacokinetics and reducing systemic side effects to improve patient outcomes. iSPERSE is a proprietary technology that allows a broad range of drugs to be formulated as small, dense, and dispersible particles for efficient drug delivery and deep penetration into the lungs.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pulmatrix Reports Q1 Earnings with Cash Position Insights
- Earnings Performance: Pulmatrix reported a Q1 GAAP EPS of -$0.32, indicating challenges in profitability that may affect investor confidence and market perception.
- Cash Flow Status: As of March 31, 2026, the company's cash and cash equivalents stood at $3.3 million, down from $4.1 million as of December 31, 2025, reflecting liquidity pressures that could impact operational flexibility.
- Operational Efficiency Outlook: The company anticipates that its current cash position, driven by operational efficiencies and spending prioritization, is sufficient to fund operations at least through the anticipated merger closing with Eos, suggesting a cautiously optimistic future.
- Merger Prospects: Despite the current financial challenges, the proposed merger with Eos could present new growth opportunities, strategically aiding in improving the overall financial health of the company.
See More
Pulmatrix Announces Merger Agreement with Eos SENOLYTIX
- Merger Agreement: Pulmatrix entered into a merger agreement with Eos SENOLYTIX on March 26, 2026, with an anticipated closing in Q3 2026, which will allow Eos's operations to continue as the core of the combined entity, enhancing market competitiveness.
- Financing Update: Concurrent with the merger agreement, Pulmatrix secured $1 million in preferred stock private placement from an affiliate of Eos, providing essential funding to support the merger process and operational needs.
- Financial Overview: As of March 31, 2026, Pulmatrix reported cash and cash equivalents of $3.324 million, down from $4.088 million as of December 31, 2025, indicating financial pressure but sufficient to fund operations until the merger is completed.
- R&D Expenditure: The company reported R&D expenses of less than $100,000 in Q1 2026, reflecting a halt in clinical development as management focuses on licensing or monetizing clinical assets to optimize resource allocation.
See More
Pulmatrix Closes Series B Preferred Stock Financing
- Financing Amount: Pulmatrix has completed a private placement of Series B Convertible Preferred Stock with Eos SENOLYTIX, raising approximately $1 million, which is intended for working capital and general corporate purposes, thereby enhancing the company's financial flexibility.
- Conversion Price: The preferred stock has a conversion price of $2.20 per share, allowing holders to convert into common stock after 90 days from issuance, providing investors with a potential capital appreciation opportunity that could attract further market interest.
- Merger Process: This financing is part of Pulmatrix's planned merger with Eos, indicating that the company has gained investor confidence during the acquisition process, which may lay the groundwork for future business integration and enhance market competitiveness.
- Shareholder Voting Rights: Holders of the Series B Preferred Stock have voting rights equivalent to common stockholders, which not only enhances investor engagement but may also have significant implications for future corporate governance and decision-making processes.
See More
Biotech Landscape Update: Regulatory Approvals and Mergers
- Anavex Drug Withdrawal: Anavex Life Sciences Corp. (AVXL) withdrew its EU marketing application for Alzheimer's drug Blarcamesine after the EMA's CHMP indicated it could not issue a positive opinion, marking a significant setback for the company's lead candidate despite continued support from patient groups.
- Quoin FDA Alignment: Quoin Pharmaceuticals Ltd. (QNRX) received positive feedback from the FDA confirming that a single Phase 3 trial may suffice for U.S. approval of QRX003 for Netherton Syndrome, with plans to initiate Phase 3 in 2026 and potentially file an NDA in 2027.
- Corcept Drug Approval: Corcept Therapeutics Inc. (CORT) secured FDA approval for Lifyorli combined with nab-paclitaxel to treat platinum-resistant ovarian cancer, based on Phase 3 ROSELLA trial results involving 381 patients, marking the first FDA-approved selective glucocorticoid receptor antagonist.
- Merck Acquires Terns: Merck (MRK) announced a definitive agreement to acquire Terns Pharmaceuticals for $53.00 per share, totaling approximately $6.7 billion, which is expected to enhance Merck's presence in hematology, with the transaction anticipated to close in Q2 2026.
See More
Pulmatrix Merges with Eos SENOLYTIX to Enhance Health Span
- Merger Agreement: Pulmatrix Inc. has agreed to merge with Eos SENOLYTIX, Inc., with the combined entity set to operate under the Eos SENOLYTIX name and trade on Nasdaq as 'EOSX', marking a strategic shift towards enhancing health span.
- Financing Support: The merger is backed by $19 million in new private financing, including a $1 million investment into Pulmatrix and bridge financing for Eos, which will facilitate the advancement of Eos's lead candidate PTC-2105, indicating strong market confidence in the technology.
- Technological Innovation: Eos's MitoXcel AI-driven geropeptide technology aims to improve body composition by increasing lean mass and reducing visceral fat rather than merely focusing on weight loss, showcasing the company's innovative approach in obesity treatment that could redefine traditional methodologies.
- Shareholder Structure Change: Following the merger, Pulmatrix shareholders are expected to own about 6% of the combined company, while Eos shareholders and financing participants will hold approximately 94%, reflecting Eos's dominant position in the merger, which is anticipated to close in mid-2026.
See More
Pulmatrix Inc. Enters Definitive Agreement to Acquire Eos Senolytix Inc.
- Merger Announcement: Pulmatrix Inc. has announced a definitive agreement to merge with Eos Senolytix Inc., with the transaction expected to close in mid-2026, marking a significant strategic expansion for the company as it will trade under the name Eos Senolytix on Nasdaq.
- Equity Structure Change: Post-merger, pre-merger Pulmatrix shareholders are expected to own approximately 6% of the combined entity, while Eos shareholders will hold about 94%, which will influence future governance and decision-making processes within the new company.
- Financing Support: The transaction includes $19 million in private financing, which features a $1 million investment in Pulmatrix, with proceeds aimed at supporting the development of Eos's MitoXcel platform and its lead clinical candidate PTC-2105, targeting age-related diseases.
- Leadership Transition: Following the merger, Eos CEO Kevin Slawin is expected to lead the combined company, a leadership change that could significantly impact the strategic direction and market performance of the new entity.
See More
Pulmatrix Reports Q1 Earnings with Cash Position Insights
- Earnings Performance: Pulmatrix reported a Q1 GAAP EPS of -$0.32, indicating challenges in profitability that may affect investor confidence and market perception.
- Cash Flow Status: As of March 31, 2026, the company's cash and cash equivalents stood at $3.3 million, down from $4.1 million as of December 31, 2025, reflecting liquidity pressures that could impact operational flexibility.
- Operational Efficiency Outlook: The company anticipates that its current cash position, driven by operational efficiencies and spending prioritization, is sufficient to fund operations at least through the anticipated merger closing with Eos, suggesting a cautiously optimistic future.
- Merger Prospects: Despite the current financial challenges, the proposed merger with Eos could present new growth opportunities, strategically aiding in improving the overall financial health of the company.
See More
Pulmatrix Announces Merger Agreement with Eos SENOLYTIX
- Merger Agreement: Pulmatrix entered into a merger agreement with Eos SENOLYTIX on March 26, 2026, with an anticipated closing in Q3 2026, which will allow Eos's operations to continue as the core of the combined entity, enhancing market competitiveness.
- Financing Update: Concurrent with the merger agreement, Pulmatrix secured $1 million in preferred stock private placement from an affiliate of Eos, providing essential funding to support the merger process and operational needs.
- Financial Overview: As of March 31, 2026, Pulmatrix reported cash and cash equivalents of $3.324 million, down from $4.088 million as of December 31, 2025, indicating financial pressure but sufficient to fund operations until the merger is completed.
- R&D Expenditure: The company reported R&D expenses of less than $100,000 in Q1 2026, reflecting a halt in clinical development as management focuses on licensing or monetizing clinical assets to optimize resource allocation.
See More
Pulmatrix Closes Series B Preferred Stock Financing
- Financing Amount: Pulmatrix has completed a private placement of Series B Convertible Preferred Stock with Eos SENOLYTIX, raising approximately $1 million, which is intended for working capital and general corporate purposes, thereby enhancing the company's financial flexibility.
- Conversion Price: The preferred stock has a conversion price of $2.20 per share, allowing holders to convert into common stock after 90 days from issuance, providing investors with a potential capital appreciation opportunity that could attract further market interest.
- Merger Process: This financing is part of Pulmatrix's planned merger with Eos, indicating that the company has gained investor confidence during the acquisition process, which may lay the groundwork for future business integration and enhance market competitiveness.
- Shareholder Voting Rights: Holders of the Series B Preferred Stock have voting rights equivalent to common stockholders, which not only enhances investor engagement but may also have significant implications for future corporate governance and decision-making processes.
See More
Biotech Landscape Update: Regulatory Approvals and Mergers
- Anavex Drug Withdrawal: Anavex Life Sciences Corp. (AVXL) withdrew its EU marketing application for Alzheimer's drug Blarcamesine after the EMA's CHMP indicated it could not issue a positive opinion, marking a significant setback for the company's lead candidate despite continued support from patient groups.
- Quoin FDA Alignment: Quoin Pharmaceuticals Ltd. (QNRX) received positive feedback from the FDA confirming that a single Phase 3 trial may suffice for U.S. approval of QRX003 for Netherton Syndrome, with plans to initiate Phase 3 in 2026 and potentially file an NDA in 2027.
- Corcept Drug Approval: Corcept Therapeutics Inc. (CORT) secured FDA approval for Lifyorli combined with nab-paclitaxel to treat platinum-resistant ovarian cancer, based on Phase 3 ROSELLA trial results involving 381 patients, marking the first FDA-approved selective glucocorticoid receptor antagonist.
- Merck Acquires Terns: Merck (MRK) announced a definitive agreement to acquire Terns Pharmaceuticals for $53.00 per share, totaling approximately $6.7 billion, which is expected to enhance Merck's presence in hematology, with the transaction anticipated to close in Q2 2026.
See More
Pulmatrix Merges with Eos SENOLYTIX to Enhance Health Span
- Merger Agreement: Pulmatrix Inc. has agreed to merge with Eos SENOLYTIX, Inc., with the combined entity set to operate under the Eos SENOLYTIX name and trade on Nasdaq as 'EOSX', marking a strategic shift towards enhancing health span.
- Financing Support: The merger is backed by $19 million in new private financing, including a $1 million investment into Pulmatrix and bridge financing for Eos, which will facilitate the advancement of Eos's lead candidate PTC-2105, indicating strong market confidence in the technology.
- Technological Innovation: Eos's MitoXcel AI-driven geropeptide technology aims to improve body composition by increasing lean mass and reducing visceral fat rather than merely focusing on weight loss, showcasing the company's innovative approach in obesity treatment that could redefine traditional methodologies.
- Shareholder Structure Change: Following the merger, Pulmatrix shareholders are expected to own about 6% of the combined company, while Eos shareholders and financing participants will hold approximately 94%, reflecting Eos's dominant position in the merger, which is anticipated to close in mid-2026.
See More
Pulmatrix Inc. Enters Definitive Agreement to Acquire Eos Senolytix Inc.
- Merger Announcement: Pulmatrix Inc. has announced a definitive agreement to merge with Eos Senolytix Inc., with the transaction expected to close in mid-2026, marking a significant strategic expansion for the company as it will trade under the name Eos Senolytix on Nasdaq.
- Equity Structure Change: Post-merger, pre-merger Pulmatrix shareholders are expected to own approximately 6% of the combined entity, while Eos shareholders will hold about 94%, which will influence future governance and decision-making processes within the new company.
- Financing Support: The transaction includes $19 million in private financing, which features a $1 million investment in Pulmatrix, with proceeds aimed at supporting the development of Eos's MitoXcel platform and its lead clinical candidate PTC-2105, targeting age-related diseases.
- Leadership Transition: Following the merger, Eos CEO Kevin Slawin is expected to lead the combined company, a leadership change that could significantly impact the strategic direction and market performance of the new entity.
See More
